中国成本-效用研究中效用值质量的现状和展望  

The Present Situation of the Quality of Utility Values in the Study of Cost-Utility in China

作　　者：杨智豪 蒋杰[2] 洪艳明 罗南[3] YANG Zhi-Hao;JIANG Jie;HONG Yan-Ming;LUO Nan(School of Health and Medicine Management,Guizhou Medical University,Gui'an 550025,China;School of pharmacy,Jinan University,Guangzhou 510632,China;Saw Swee Hock School of public health,National University of Singapore,Singapore 117549)

机构地区：[1]贵州医科大学医药卫生管理学院,贵安550025 [2]暨南大学药学院,广州510632 [3]新加坡国立大学苏瑞福公共卫生学院,新加坡117549

出　　处：《中国药物经济学》2022年第6期33-40,共8页China Journal of Pharmaceutical Economics

基　　金：中国博士后科学基金(2019M663408);广州市科技计划项目(201704020198)。

摘　　要：目的 了解已发表的中国成本-效用研究中健康状态效用值(HSU)数据的出处,对其获取方法和汇报质量以及发展趋势进行研究分析。方法 通过制定专业检索策略在中国期刊全文数据库、万方数据知识服务平台和中文期刊全文数据库中查找中国已发表的成本-效用HSU文献,提取文献基本情况、研究内容及HSU相关信息,建立Excel数据库并进行描述性统计分析。结果 最终获得234篇文章和1061个HSU数据。其中绝大多数文章主要从已发表的文献中获取HSU(n=743,70.0%),但并未对相关文献进行系统综述(n=217,90.7%)。在评估方法上,有266个HSU说明了使用五维健康量表(EQ-5D)进行测量,且在过去10年呈上升趋势。结论 目前已发表的成本-效用研究中HSU数据主要来源于已发表的文献,但并未对所有相关数据或文献进行综述分析。在汇报时,缺乏对HSU相关信息的描述,且这一问题呈逐年上升趋势。国内研究人员应根据最新药物经济学评价指南的指导意见,重视成本-效用研究的数据质量,从而提高经济学评价结果的严谨度和可信度。Objective To analyze the methods of obtaining HSU data and the quality of reporting HSU data and to report their development trend to make suggestions for future study.Methods A systematic search and selection process was carried out in CNKI,Wanfang and Weipu database to identify all relevant published research.Data was extracted into Excel and results were summarized and reported.Results In total,234 articles and 1 061 HSU were obtained.Most HSUs(n=743,70.0%) were obtained from published literature.Most of the articles did not conduct a systematic review to obtain HSUs(n=217,92.7%).In terms of assessment methods,266 HSUs described the use of the five dimensional health scale(EQ-5D) for measurement,which has shown an upward trend in the past 10 years.Conclusion Most of the articles obtained HSU data from published studies but did not obtain the data through a systematic review.In addition,published articles did not report sufficient information of the HSU used,such as the source of value set,source of HRQoL data,sample size,etc.,and the trend continued to grow.Chinese researchers should stick to the Pharmacoeconomics evaluation guideline and pay more attention to the HSU quality used for CUA research,strengthening its preciseness and credibility.

关 键 词：成本-效用分析 健康状态效用值 药物经济学评价 

分 类 号：R956[医药卫生—药学]